Syndromic beta-thalassemia

Syndromic beta-thalassemia (Orphanet code 231386) refers to a group of rare genetic conditions in which beta-thalassemia — a disorder of reduced or absent beta-globin chain production leading to ineffective erythropoiesis and chronic anemia — occurs as part of a broader clinical syndrome affecting multiple organ systems. Unlike isolated beta-thalassemia, these syndromic forms involve additional clinical features beyond the hematological manifestations, which may include intellectual disability, developmental delay, skeletal anomalies, facial dysmorphism, and other congenital malformations depending on the specific subtype. Several distinct entities fall under this classification. These include beta-thalassemia associated with large chromosomal deletions on chromosome 11p15.5 that remove the beta-globin gene cluster along with neighboring genes, resulting in additional features such as developmental delay and dysmorphic features. Other subtypes may involve contiguous gene deletion syndromes or specific genetic rearrangements that disrupt both the beta-globin locus and adjacent genomic regions. The hematological component typically presents with microcytic hypochromic anemia of variable severity, ranging from thalassemia trait to thalassemia intermedia or major phenotypes. Management of syndromic beta-thalassemia requires a multidisciplinary approach. The thalassemia component may necessitate regular blood transfusions, iron chelation therapy, folic acid supplementation, and in some cases hematopoietic stem cell transplantation. The additional syndromic features require individualized management depending on the organs involved, which may include developmental support services, orthopedic interventions, and regular monitoring of affected systems. Genetic counseling is essential for affected families to understand recurrence risks and the specific genetic mechanism involved.

Common questions about Syndromic beta-thalassemia